EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation

Shibo Gao, Yukun Liu, Jinglin Kong, Linkuan Huangfu, Yuchuan Yang, Haiyang Cui, Xiaocong Sun, Shuling Shi, Daoke Yang

Cancer Management and Research · 2025-04 · Volume 17 · 835-850

DOI: 10.2147/cmar.s510217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Management and Research, 2025-04. Verfasst von Shibo Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Objective: To explore the prognostic factors affecting patients with glioblastoma (GBM) treated with the Stupp regimen and establish a prediction model based on hematological indicators to guide future clinical decision - making.

Methods

A total of 271 GBM patients meeting the screening criteria were recruited. They were randomly divided into a training set (190 cases) and a validation set (81 cases) at a 7:3 ratio. The training set was utilized to establish a comprehensive hematology prognostic scoring system (CHPSS), and the validation set was employed to verify the CHPSS. A Risk Score (RS) was computed from the CHPSS, and a nomogram model was constructed to predict patients' overall survival (OS) based on the RS. Additionally, the relationship between RS and the surgery - to - radiotherapy interval (SRI) was analyzed.

Results

Patients were categorized into low - risk and high - risk groups according to the RS calculated by CHPSS. The overall survival of patients in these two groups differed significantly. The C - indices of the nomogram model constructed based on RS and clinical features were 0.79 and 0.73 in the training and validation sets, respectively. The clinical decision curve showed that when the threshold probability exceeded 20%, the model's prediction provided the greatest net benefit for GBM patients receiving the Stupp regimen. In the overall cohort, a correlation between RS and SRI was observed, allowing for the classification of SRI into different risk subgroups based on RS.

Conclusion

The nomogram model based on CHPSS can effectively evaluate the prognosis of glioblastoma patients.

Schlagwörter

Stichwörter der Autor:innen

preoperative hematologic indicatorsprognostic scoring systemrisk scoresurgery-to-radiotherapy interval

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.

Zitieren

APA

Gao, S., Liu, Y., Kong, J., Huangfu, L., Yang, Y., Cui, H., Sun, X., Shi, S., & Yang, D. (2025). Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation. Cancer Management and Research, Volume 17, 835-850. https://doi.org/10.2147/cmar.s510217

Vancouver

Gao S, Liu Y, Kong J, Huangfu L, Yang Y, Cui H, et al. Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation. Cancer Management and Research. 2025;Volume 17:835-850. doi:10.2147/cmar.s510217

BibTeX
@article{Gao2025,
  author = {Gao, Shibo and Liu, Yukun and Kong, Jinglin and Huangfu, Linkuan and Yang, Yuchuan and Cui, Haiyang and Sun, Xiaocong and Shi, Shuling and Yang, Daoke},
  title = {Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation},
  journal = {Cancer Management and Research},
  year = {2025},
  volume = {Volume 17},
  pages = {835--850},
  doi = {10.2147/cmar.s510217}
}
Kostenlos starten →